ProShare Advisors
ANTH

ProShare Advisors’s Anthera Pharmaceuticals, Inc. ANTH Stock Holding History

ProShare Advisors’s Portfolio ANTH Stock Details ANTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3,749
Closed -$94K – 1767
2016
Q3 		$94K Sell
3,749
-666
-15% -$16.8K ﹤0.01% 1421
2016
Q2 		$109K Buy
4,415
+146
+3% +$4.13K ﹤0.01% 1516
2016
Q1 		$124K Sell
4,269
-461
-10% -$12.5K ﹤0.01% 1498
2015
Q4 		$176K Buy
+4,730
New +$209K ﹤0.01% 1570

Other funds holding ANTH

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

ProShare Advisors's ANTH Position: Q4 2016 in Review

ProShare Advisors sold out of Anthera Pharmaceuticals, Inc. (ANTH) in Q4 2016, closing a stake of 3,749 shares — an estimated $94K sold.

ProShare Advisors first reported a position in ANTH in Q4 2015 and held it in 4 quarters. The position peaked at $176K in Q4 2015. 72 funds tracked by Wall St. Rank hold ANTH as of Q4 2016.

  • ProShare Advisors reported no remaining Anthera Pharmaceuticals, Inc. position as of Q4 2016 after selling out during the quarter.
  • ProShare Advisors sold 3,749 Anthera Pharmaceuticals, Inc. shares in Q4 2016, an estimated $94K.
  • ProShare Advisors first reported a position in Anthera Pharmaceuticals, Inc. in Q4 2015 and held it in 4 quarters.
  • ProShare Advisors's Anthera Pharmaceuticals, Inc. position peaked at $176K in Q4 2015.
  • 72 funds tracked by Wall St. Rank held Anthera Pharmaceuticals, Inc. as of Q4 2016.

Based on ProShare Advisors's 13F filing for Q4 2016, filed 13 Feb 2017.